Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

PRESS RELEASE Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of…

Related Keywords

United States ,Canada ,Belgium ,American ,Cian Crosbie ,Jonathan Edwards ,Nick Bastin ,York Heart Association ,Strategic Communications ,Company Or Sequanamedical ,Sequana Medical ,Euronext Brussels ,Safety Monitoring Board ,Chief Medical Officer ,Chief Executive Officer ,New York Heart Association ,Seattle Heart Failure ,North American ,Pre Market Approval ,